IBM Announces Deals With Apple, Johnson & Johnson, and Medtronic In Bid To Transform Health Care by Matthew Herper, Forbes Staff
Reporter: Aviva Lev-Ari, PhD, RN
Big Blue is certainly putting some muscle into medicine. Some 2,000 employees will be involved in a new Watson-in-medicine business unit. The Armonk, N.Y.-based computing giant is making two acquisitions, too, buying Cleveland’s Explorys, an analytics company that has access to 50 million medical records from U.S. patients, and Dallas’ Phytel, a healthcare services head of IBM’s Life Science company that provides feedback to doctors and patients for follow-up care. Deal prices were not disclosed.
It is also announcing some big partnerships:
• Apple AAPL +3.6% will work to integrate Watson-based apps into its HealthKit and ResearchKit tool systems for developers, which allow the collection of personal health data and the use of such data in clinical trials.
• Johnson & Johnson JNJ +0.95%, which is one of the largest makers of knee and hip implants, will use Watson to create a personal concierge service to prepare patients for knee surgery and to help them deal with its after effects.
• Medtronic MDT +0.18%, the maker of implantable heart devices and diabetes products, will use Watson to create an “internet of things” around its medical gadgets, collecting data both for patients’ personal use and, once it’s anonymized, for understanding how well the devices are working. Initially, the focus is on diabetes.
SOURCE
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
vaishnavee24
zraviv06
zs22
Leave a Reply